玫瑰痤疮与代谢性疾病相关研究进展

doi:10.35541/cjd.20230523

中华皮肤科杂志 ›› 2025, e0230523.doi: 10.35541/cjd.20230523

玫瑰痤疮与代谢性疾病相关研究进展

肖雪娟谢红付李吉赵志祥

中南大学湘雅医院皮肤病医院衰老生物学湖南省重点实验室国家老年疾病临床医学研究中心（湘雅医院），长沙 410008

收稿日期:2023-09-11 修回日期:2024-02-18 发布日期:2025-09-22
通讯作者: 赵志祥 E-mail:zhaozhixiang@csu.edu.cn

Association between rosacea and metabolic diseases

Xiao Xuejuan, Xie Hongfu, Li Ji, Zhao Zhixiang

Department of Dermatology, Xiangya Hospital of Central South University, Hunan Key Laboratory of Aging Biology, National Clinical Research Center for Geriatric Disorders, Changsha 410008, China

Received:2023-09-11 Revised:2024-02-18 Published:2025-09-22
Contact: Zhao Zhixiang E-mail:zhaozhixiang@csu.edu.cn

摘要/Abstract

摘要： 【摘要】玫瑰痤疮是一种临床常见的慢性炎症性皮肤病，近年研究表明，玫瑰痤疮与代谢性疾病密切相关；玫瑰痤疮患者往往同时合并有肥胖、脂代谢紊乱、胰岛素抵抗等代谢综合征，并容易罹患甲状腺功能紊乱、高尿酸血症及其他代谢性疾病。本文综述玫瑰痤疮与代谢综合征、内分泌相关代谢性疾病及代谢组学的研究进展。

关键词: 红斑痤疮, 代谢疾病, 代谢综合征, 胰岛素抵抗, 血脂异常, 代谢组学

Abstract: 【Abstract】 Rosacea is a common chronic inflammatory skin disorder, and recent studies have shown a close association between rosacea and metabolic diseases. Patients with rosacea often have concomitant conditions such as obesity, dyslipidemia, insulin resistance, and other components of metabolic syndrome, and are also at an increased risk of thyroid dysfunction, hyperuricemia, and other metabolic disorders. This article reviews the research progress on the relationship between rosacea and metabolic syndrome, endocrine-related metabolic diseases, and metabolomics.

Key words: Rosacea, Metabolic diseases, Metabolic syndrome, Insulin resistance, Dyslipidemias, Metabolomics

肖雪娟谢红付李吉赵志祥. 玫瑰痤疮与代谢性疾病相关研究进展[J]. 中华皮肤科杂志, 2025,e0230523. doi:10.35541/cjd.20230523

Xiao Xuejuan, Xie Hongfu, Li Ji, Zhao Zhixiang. Association between rosacea and metabolic diseases[J]. Chinese Journal of Dermatology,2025,e0230523. doi:10.35541/cjd.20230523

参考文献 38

［1］	Li J, Wang B, Deng Y, et al. Epidemiological features of rosacea in Changsha, China: a population⁃based, cross⁃sectional study［J］. J Dermatol, 2020,47（5）:497⁃502. doi: 10.1111/1346⁃8138. 15301.
［2］	Deng Z, Chen M, Zhao Z, et al. Whole genome sequencing identifies genetic variants associated with neurogenic inflammation in rosacea［J］. Nat Commun, 2023,14（1）:3958. doi: 10.1038/s41467⁃023⁃39761⁃2.
［3］	Akin Belli A, Ozbas Gok S, Akbaba G, et al. The relationship between rosacea and insulin resistance and metabolic syndrome［J］. Eur J Dermatol, 2016,26（3）:260⁃264. doi: 10.1684/ejd. 2016.2748.
［4］	Akin Belli A, Alatas ET, Kara Polat A, et al. Assessment of thyroid disorders in patients with rosacea: a large case⁃control study［J］. An Bras Dermatol, 2021,96（5）:539⁃543. doi: 10.1016/j.abd.2021.02.004.
［5］	Nam JH, Yang J, Park J, et al. Association between rosacea severity and relative muscle mass: a cross⁃sectional study［J］. J Dermatol, 2019,46（1）:11⁃17. doi: 10.1111/1346⁃8138.14689.
［6］	Chen Q, Shi X, Tang Y, et al. Association between rosacea and cardiometabolic disease: a systematic review and meta⁃analysis［J］. J Am Acad Dermatol, 2020,83（5）:1331⁃1340. doi: 10.1016/j.jaad.2020.04.113.
［7］	Li S, Cho E, Drucker AM, et al. Obesity and risk for incident rosacea in US women［J］. J Am Acad Dermatol, 2017,77（6）:1083⁃1087.e5. doi: 10.1016/j.jaad.2017.08.032.
［8］	Huang PL. A comprehensive definition for metabolic syndrome［J］. Dis Model Mech, 2009,2（5⁃6）:231⁃237. doi: 10.1242/dmm. 001180.
［9］	Jiang CQ, Xu L, Zhang WS, et al. Adiposity and mortality in older Chinese: an 11⁃year follow⁃up of the Guangzhou Biobank Cohort Study［J］. Sci Rep, 2020,10（1）:1924. doi: 10.1038/s41598⁃020⁃58633⁃z.
［10］	应洁雅, 相文忠, 宋秀祖. 代谢综合征与皮肤病［J］. 中华皮肤科杂志, 2021,54（7）:642⁃645. doi: 10.35541/cjd.20191018.
［11］	Su X, Chen X, Wang B. Pathology of metabolically⁃related dyslipidemia［J］. Clin Chim Acta, 2021,521:107⁃115. doi: 10. 1016/j.cca.2021.06.029.
［12］	Su X, Cheng Y, Chang D. Lipid⁃lowering therapy: guidelines to precision medicine［J］. Clin Chim Acta, 2021,514:66⁃73. doi: 10.1016/j.cca.2020.12.019.
［13］	Berberich AJ, Hegele RA. A modern approach to dyslipidemia［J］. Endocr Rev, 2022,43（4）:611⁃653. doi: 10.1210/endrev/bnab037.
［14］	Duman N, Ersoy Evans S, Atakan N. Rosacea and cardiovascular risk factors: a case control study［J］. J Eur Acad Dermatol Venereol, 2014,28（9）:1165⁃1169. doi: 10.1111/jdv.12234.
［15］	Haber R, El Gemayel M. Comorbidities in rosacea: a systematic review and update［J］. J Am Acad Dermatol, 2018,78（4）:786⁃792.e8. doi: 10.1016/j.jaad.2017.09.016.
［16］	Spoendlin J, Voegel JJ, Jick SS, et al. A study on the epidemiology of rosacea in the U.K［J］. Br J Dermatol, 2012,167（3）:598⁃605. doi: 10.1111/j.1365⁃2133.2012.11037.x.
［17］	Reszke R, Pełka D, Walasek A, et al. Skin disorders in elderly subjects［J］. Int J Dermatol, 2015,54（9）:e332⁃e338. doi: 10.1111/ijd.12832.
［18］	Aldrich N, Gerstenblith M, Fu P, et al. Genetic vs environmental factors that correlate with rosacea: a cohort⁃based survey of twins［J］. JAMA Dermatol, 2015,151（11）:1213⁃1219. doi: 10.1001/jamadermatol.2015.2230.
［19］	Demir S, Nawroth PP, Herzig S, et al. Emerging targets in type 2 diabetes and diabetic complications［J］. Adv Sci （Weinh）, 2021,8（18）:e2100275. doi: 10.1002/advs.202100275.
［20］	Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance［J］. Nature, 2006,440（7086）:944⁃948. doi: 10.1038/nature04634.
［21］	Spoendlin J, Voegel JJ, Jick SS, et al. Risk of rosacea in patients with diabetes using insulin or oral antidiabetic drugs［J］. J Invest Dermatol, 2013,133（12）:2790⁃2793. doi: 10.1038/jid.2013.225.
［22］	Li Y, Guo L, Hao D, et al. Association between rosacea and cardiovascular diseases and related risk factors: a systematic review and meta⁃analysis［J］. Biomed Res Int, 2020,2020:7015249. doi: 10.1155/2020/7015249.
［23］	Li Y, Yang L, Wang Y, et al. Exploring metformin as a candidate drug for rosacea through network pharmacology and experimental validation［J］. Pharmacol Res, 2021,174:105971. doi: 10.1016/j.phrs.2021.105971.
［24］	Li WQ, Zhang M, Danby FW, et al. Personal history of rosacea and risk of incident cancer among women in the US［J］. Br J Cancer, 2015,113（3）:520⁃523. doi: 10.1038/bjc.2015.217.
［25］	Egeberg A, Fowler JF Jr, Gislason GH, et al. Rosacea and risk of cancer in Denmark［J］. Cancer Epidemiol, 2017,47:76⁃80. doi: 10.1016/j.canep.2017.01.006.
［26］	Izikson L, English JC 3rd, Zirwas MJ. The flushing patient: differential diagnosis, workup, and treatment［J］. J Am Acad Dermatol, 2006,55（2）:193⁃208. doi: 10.1016/j.jaad.2005.07.057.
［27］	İkizoğlu G. Red face revisited: flushing［J］. Clin Dermatol, 2014,32（6）:800⁃808. doi: 10.1016/j.clindermatol.2014.02.019.
［28］	Demiray A, Afsar B, Covic A, et al. The role of uric acid in the acute myocardial infarction: a narrative review［J］. Angiology, 2022,73（1）:9⁃17. doi: 10.1177/00033197211012546.
［29］	Karaosmanoglu N, Karaaslan E, Ozdemir Cetinkaya P. Evaluation of serum uric acid levels in patients with rosacea［J］. Arch Dermatol Res, 2020,312（6）:447⁃451. doi: 10.1007/s00403⁃020⁃02033⁃w.
［30］	Bechstein SK, Ochsendorf F. Acne and rosacea in pregnancy［J］. Hautarzt, 2017,68（2）:111⁃119. doi: 10.1007/s00105⁃016⁃3918⁃8.
［31］	Wu WH, Geng H, Cho E, et al. Reproductive and hormonal factors and risk of incident rosacea among US White women［J］. J Am Acad Dermatol, 2022,87（1）:138⁃140. doi: 10.1016/j.jaad.2021.06.865.
［32］	Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation［J］. Physiol Rev, 2009,89（1）:147⁃191. doi: 10.1152/physrev.00010.2008.
［33］	Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development［J］. Nat Rev Gastroenterol Hepatol, 2014,11（1）:55⁃67. doi: 10.1038/nrgastro.2013.151.
［34］	Fan M, Wang Y, Jin L, et al. Bile acid⁃mediated activation of brown fat protects from alcohol⁃induced steatosis and liver injury in mice［J］. Cell Mol Gastroenterol Hepatol, 2022,13（3）:809⁃826. doi: 10.1016/j.jcmgh.2021.12.001.
［35］	Xiao W, Chen M, Peng Q, et al. Lithocholic acid promotes rosacea⁃like skin inflammation via G protein⁃coupled bile acid receptor 1［J］. Biochim Biophys Acta Mol Basis Dis, 2022,1868（12）:166563. doi: 10.1016/j.bbadis.2022.166563.
［36］	Liu T, Xiao W, Chen M, et al. Aberrant amino acid metabolism promotes neurovascular reactivity in rosacea［J］. JCI Insight, 2022,7（22）:e161870. doi: 10.1172/jci.insight.161870.
［37］	Ekiz O, Balta I, Sen BB, et al. Vitamin D status in patients with rosacea［J］. Cutan Ocul Toxicol, 2014,33（1）:60⁃62. doi: 10. 3109/15569527.2013.797907.
［38］	Akdogan N, Alli N, Incel Uysal P, et al. Role of serum 25⁃hydroxyvitamin D levels and vitamin D receptor gene polymorphisms in patients with rosacea: a case⁃control study［J］. Clin Exp Dermatol, 2019,44（4）:397⁃403. doi: 10.1111/ced. 13769.

[1]	林尽染梁晓进刘庆梅吴文育. 雄激素性秃发与代谢综合征的关联：从发病机制到治疗策略[J]. 中华皮肤科杂志, 2025, 58(7): 591-594.
[2]	梁高澎杨显杰陈奇权宋志强. 慢性荨麻疹共病的研究现状及进展[J]. 中华皮肤科杂志, 2025, 58(6): 567-572.
[3]	陈良宏孙艳王敬玉吴严. 本维莫德在皮肤病中的研究进展[J]. 中华皮肤科杂志, 2025, 58(3): 266-268.
[4]	刘厚广申宜魏琼玲李峥霍姗姗谢广成刘英文. 过表达或抑制细胞周期蛋白依赖性激酶2对A375细胞代谢组的影响[J]. 中华皮肤科杂志, 2025, 0(2): 20240442-e20240442.
[5]	杨开颖田博闻蓝超婷. 基于非靶向代谢组学分析婴幼儿血管瘤内皮细胞代谢特征[J]. 中华皮肤科杂志, 2024, 57(7): 601-609.
[6]	陈竹董丽萍肖风丽. 基于代谢组学探究特应性疾病的研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220366-e20220366.
[7]	潘婼芯顾多多张悦李敏陶梦许阳. 代谢组学在玫瑰痤疮研究中的应用进展[J]. 中华皮肤科杂志, 2024, 57(2): 178-181.
[8]	魏子妤杨勇. 离子通道与玫瑰痤疮发病机制的研究进展[J]. 中华皮肤科杂志, 2024, 57(2): 174-177.
[9]	刘亭微孟潇琦顾多多潘婼芯张悦许阳. 玫瑰痤疮发病机制的研究进展[J]. 中华皮肤科杂志, 2024, 57(2): 186-190.
[10]	张悦陶梦李敏姜沛彧刘韵祎刘乙萱潘婼芯许阳. 玫瑰痤疮病情评价标准研究进展[J]. 中华皮肤科杂志, 2024, 57(2): 182-185.
[11]	李吉谢红付. 如何避免玫瑰痤疮的误诊[J]. 中华皮肤科杂志, 2024, 57(2): 119-122.
[12]	蒋献宋德宇. [开放获取] 从心身医学视角认识玫瑰痤疮[J]. 中华皮肤科杂志, 2024, 57(2): 123-126.
[13]	那君李若瑜仲少敏杨莉吴艳. 玫瑰痤疮真实世界诊疗现状调查分析[J]. 中华皮肤科杂志, 2024, 57(2): 127-133.
[14]	马光荣谢红付刘家双周钟莲周淞麒黄莹雪李吉. 玫瑰痤疮患者小肠细菌过度生长情况调查及临床特征分析[J]. 中华皮肤科杂志, 2024, 57(2): 134-140.
[15]	杨璐, 王珍珍施影钟慧婷余圆圆马寒陈燕清, . 基于代谢组学分析海分枝杆菌对巨噬细胞的影响[J]. 中华皮肤科杂志, 2024, 57(11): 1037-1044.

玫瑰痤疮与代谢性疾病相关研究进展

Association between rosacea and metabolic diseases

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 38

相关文章 15

Metrics

本文评价

推荐阅读 10